Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem ...

The stock's fall snapped a five-day winning streak.

Bristol-Myers Squibb (NYSE:BMY) announced positive results from the Phase 3 POETYK PsA-1 trial of Sotyktu, showcasing its ...

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Bristol Myers Squibb has appointed Wendy Bartie as EVP, corporate affairs. Bartie started in the role this month, BMS said on ...

Under this deal, Philochem will grant RayzeBio exclusive worldwide rights to develop, manufacture, and market OncoACP3, a ...

Bristol Myers Squibb presents data across targeted protein degradation research including CELMoD agents and BCL6 ligand-directed degrader at EHA 2025: Princeton, New Jersey Friday ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Bristol-Myers Squibb (NYSE:BMY) recently announced a significant partnership with BioNTech SE to co-develop and ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...